Anthropic reports early drug-development results with Claude across six partners, from CAR-T to regulatory filings

On October 27, 2026, Anthropic published early results from using Claude in drug development with BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group, plus its own one-person program, Mithril Medicine.

At Generate Biomedicines, six scientists used Claude Code to propose shorter designs for a CAR T-cell genetic component; one about 70 percent shorter produced roughly 10 times as many receptors in lab tests and killed tumor cells more efficiently. Divergence Labs had Claude largely autonomously generate about 35,000 antibody designs in roughly a month for food allergy; early tests found three that bound IgE and 20 that dislodged it, three of them better than the standard medication. At BigHat, about 1,010 variants of two antibody fragments were made over about 10 weeks; the best bound more than 10 times more tightly, and Claude helped replace misleading stability metrics.

At Enveda, Claude reviewed 1,061 pages of manufacturing documentation, caught all 11 issues human reviewers found plus seven more, and cut review time by 89 percent; it drafted a regulatory document in four hours versus about three months by hand. Mithril Medicine’s founder used Claude to coordinate 11 external labs and took a rare muscular dystrophy candidate from idea to promising mouse results in under 18 months.

Why it matters: the results span the pipeline - design, optimization, manufacturing documentation and trial planning - suggesting model help is not confined to the molecule-design step that earlier AI-for-drugs work focused on.

What it does not show: Anthropic says all of the work is early and mostly preclinical, so no drug has been tested in humans; several efforts (Divergence’s combination drug, Pleiades, BMS trial planning) are still in development; and the case studies are partner-reported without independent replication.

Sources

Last verified November 9, 2026